Release date: 2014-11-28
The National Institutes of Health (NIH) announced on November 26 that the first Ebola vaccine was successfully tested in clinical trials and proved to be safe and effective.
The results were published in a medical journal in the United States on the same day. According to the article, NIH's Institute of Allergy and Infectious Diseases and GlaxoSmithKline researchers extracted some of the genes from the Ebola virus and implanted them into human cells to make a vaccine.
After an animal test, the researchers began a human trial at the NIH Clinical Center in Maryland from September. The first batch of volunteers totaled 20 people, aged between 18 and 50 years old. These volunteers developed Ebola virus antibodies in the immune system after the test vaccine was vaccinated. At the same time, some volunteers showed anti-viral immune cells, also known as "T-cells." This kind of cells can effectively prevent the body from infecting the Ebola virus. The study also found that the vaccine had no significant side effects. Only two people had a brief fever due to the overdose of the vaccine.
Fuxi, head of the Institute of Allergy and Infectious Diseases, said in a statement on the 26th that the presence of antibodies and immune cells in volunteers is a positive sign. He said researchers will further test the safety of this vaccine in the United States and West African countries in the future.
Although the vaccine is currently proven to be safe and effective, studies have shown that the human immune system requires large doses of vaccine to produce enough antibodies, which means that the vaccine's production cannot meet demand in the short term.
The White House issued a statement on the 26th, congratulating the NIH team for making "milestone" progress in vaccine development. The statement also said that US President Barack Obama will visit NIH headquarters on December 2, and hopes to urge Congress to approve the budget application for the Ebola epidemic as soon as possible.
Source: China News Network
Probiotics are a class of active microorganisms that are beneficial to the host by colonizing the human body and changing the composition of the flora in a certain part of the host. By regulating the immune function of the host mucosa and system or by regulating the balance of intestinal flora, promoting nutrient absorption and maintaining intestinal health, resulting in the production of single microorganisms or mixed microorganisms with a well-defined composition that are beneficial to health
Probiotics,Acidophilus Lactobacillus,Lactobacillus Acidophilus,Lactobacillus Salivarius
SHAANXI HAIBO BIOTECHNOLOGY CO., LTD , https://www.rozenbio.com